A new consortium spearheaded by the New York Genome Center aims to foster and organize genomic COVID-19 research in the New York metropolitan area. With approximately $2.5 million in philanthropy funding to start, the COVID-19 Genomics Rese

Siemens Healthineers is adding more firepower in the fight to make more novel coronavirus (SARS-CoV-2) diagnostics available. The company said its Fast Track Diagnostics (FTD) SARS-COV-2 Assay is already being shipped in Europe for research

BillionToOne wants to expand its diagnostic offerings and its most recent financing could give it a push in that direction. The Menlo Park, CA-based company has raised $15 million in a follow-on to its series A round. With this financing, t

Tests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the latest with diagnostic contributions. Waltham, MA-based Thermo Fisher is the second company

On March 5, 2020, Amicus Therapeutics announced the official opening of its new Global Research and Gene Therapy Center of Excellence in Philadelphia, PA, to advance its portfolio of rare disease gene therapy programs. Amicus and the Univer

A new test being developed by Austin, TX-based Astrotech could detect coronavirus (COVID-19) and other lung diseases from the metabolites found in a persons breath. The companys BreathTest-1000 is a mass spectrometry technology that was ini

Dear Colleagues, We are in a challenging time as the COVID-19 pandemic rapidly accelerates in New York City. Healthcare providers will need to make critical decisions that are far different than the normal practice of medicine and will like

Outpatient testing must not be encouraged, promoted or advertised. Persons with COVID-like illness not requiring hospitalization should be instructed to stay home. It is safer for the patients and health care workers and testing does not cu

There’s a new entrant in the liquid biopsy space. Well, sort of. Even though OncoCell MDx was formed in 2012, it hasn’t made a great deal of noise up until this year.

A newly-formed partnership between Biodesix and MRM Proteomics could be the key that unlocks the door for better outcomes in lung cancer patients. Earlier this week, the two diagnostic companies announced a deal that would have Montreal-base